Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Acute Myeloid Leukemia (AML): early-phase trial registry
12 of 30 indexed Acute Myeloid Leukemia (AML) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #519 of 28,707 conditions by registered trial count.
30 US clinical trials · 12 currently recruiting · #519 of 28,707 conditions by registered trial count
Acute Myeloid Leukemia (AML): 30 US clinical trials tracked, 12 recruiting.
Acute Myeloid Leukemia (AML) is the subject of 30 registered US clinical trials on ClinicalTrials.gov, 12 of them currently open to new participants. 5 are in Phase 3-4 (later-stage) and 23 in Phase 1-2 (earlier-stage). The most active sponsor is St. Jude Children's Research Hospital, running 3 of these trials.
Enrollment posture brief
Registry condition acute-myeloid-leukemia-aml
OPEN 12 | RECR 40% | LATE 5 | EARLY 23 | RANK #519 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Achondroplasia (40% recruiting · 10 trials)
Acute Myeloid Leukemia (AML) lists 12 open slots (40% of 30 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Acute Myeloid Leukemia (AML) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Acute Myeloid Leukemia (AML) recruits in line with its size-band peers.
12 of 30 indexed trials (40%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Acute Myeloid Leukemia (AML) trials is spread across many organizations.
St. Jude Children's Research Hospital accounts for 3 of 30 trials (10%). 20 distinct sponsors appear on at least one study for this condition label.
-
Most Acute Myeloid Leukemia (AML) trials plan to enrol fewer than 100 people.
Median target enrolment is 75 among the 30 trials that report a genuine target (sentinel values excluded). 18 of those (60%) plan for fewer than 100 participants.
-
Acute Myeloid Leukemia (AML) research is mostly interventional.
30 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
30 total, page 1 of 1
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Kura Oncology
NCT07007312
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Masonic Cancer Center, University of Minnesota
NCT01962636
Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized Study
M.D. Anderson Cancer Center
NCT06811233
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
Bio-Path Holdings
NCT02781883
A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
Solu Therapeutics
NCT06950034
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
NCT05092451
Ivosidenib as Post-HSCT Maintenance for AML
Massachusetts General Hospital
NCT06707493
APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML
Aptevo Therapeutics
NCT06634394
A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)
Memorial Sloan Kettering Cancer Center
NCT05756777
A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)
Memorial Sloan Kettering Cancer Center
NCT06773208
Niclosamide in Pediatric Patients With Relapsed and Refractory AML
Stanford University
NCT05188170
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT06398457
A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy
AbbVie
NCT02993523
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
Eli Lilly and Company
NCT04603001
Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation
St. Jude Children's Research Hospital
NCT02790515
A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy
AbbVie
NCT04102020
Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN
Jacqueline Garcia, MD
NCT03613532
A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia
Astellas Pharma Global Development
NCT05520567
TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies
St. Jude Children's Research Hospital
NCT03849651
A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant
Memorial Sloan Kettering Cancer Center
NCT04872595
Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML)
Clavis Pharma
NCT01147939
Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia
Stemline Therapeutics
NCT02113982
A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission
Astellas Pharma Global Development
NCT02927262
A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy
AbbVie
NCT03941964
Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT
Center for International Blood and Marrow Transplant Research
NCT01772953
Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM
Gamida Cell
NCT01816230
Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome
St. Jude Children's Research Hospital
NCT02212561
Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers
National Heart, Lung, and Blood Institute (NHLBI)
NCT00488592
Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders
Massachusetts General Hospital
NCT01758042
Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy
National Heart, Lung, and Blood Institute (NHLBI)
NCT00433745
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 12 |
| Phase 2 | 11 |
| Phase 3 | 5 |
Top Sponsors
Named interventions
Most-linked intervention names on Acute Myeloid Leukemia (AML) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Acute Myeloid Leukemia (AML) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Acute Myeloid Leukemia (AML) page
30 registered trials, 12 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 12 Acute Myeloid Leukemia (AML) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- St. Jude Children's Research Hospital sponsors the most Acute Myeloid Leukemia (AML) trials on record, review their full trial history before evaluating a specific study. See St. Jude Children's Research Hospital's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Acute Myeloid Leukemia (AML) condition card totals 30 registered trials; most-linked intervention Venetoclax; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.